The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-12-26

AUTHORS

R Wurzel, P Ray, K Major-Walker, J Shannon, R Rittmaster

ABSTRACT

The dual 5α-reductase inhibitor, dutasteride has been shown to suppress serum dihydrotestosterone (DHT) by >90%. In the present study, the effect of dutasteride 0.5 mg/day on intraprostatic DHT levels was investigated. In this multicenter, double-blind trial, 43 men with benign prostatic hyperplasia (BPH) scheduled to undergo transurethral resection of the prostate (TURP) were randomized to receive dutasteride, 0.5 mg/day or placebo for 3 months before surgery. Intraprostatic DHT, testosterone and dutasteride levels were determined at the time of TURP. Changes in serum DHT and testosterone from baseline, and both serum and intraprostatic dutasteride levels at the time of TURP were also assessed. Dutasteride reduced intraprostatic DHT by 94% relative to placebo (P<0.001); the adjusted mean intraprostatic DHT concentration was 3.23 and 0.209 ng/g in the placebo and dutasteride groups, respectively. In the dutasteride group, serum DHT was reduced from baseline by 93% at month 3, a significantly greater reduction (P<0.001) than the 15% decrease observed in the placebo group. There was a reciprocal increase in intraprostatic testosterone but the level of intraprostatic testosterone in the dutasteride group tended to be lower than the intraprostatic DHT level in the placebo group (P=0.06). Significant intraprostatic DHT suppression was achieved in all subjects who received dutasteride, regardless of the level of intraprostatic dutasteride. There was a strong positive correlation between serum and intraprostatic dutasteride concentrations (R2=0.73). After 3 months of treatment, dutasteride 0.5 mg/day provided near-complete suppression of both intraprostatic and serum DHT in men with BPH. More... »

PAGES

149-154

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.pcan.4500931

DOI

http://dx.doi.org/10.1038/sj.pcan.4500931

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034769216

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17189955


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Azasteroids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dihydrotestosterone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dutasteride", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Hyperplasia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Testosterone", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Urology, Grove Hill Medical Center, New Britain, CT, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Urology, Grove Hill Medical Center, New Britain, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wurzel", 
        "givenName": "R", 
        "id": "sg:person.01035712243.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035712243.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Urology, Cook County Hospital, Chicago, IL, USA", 
          "id": "http://www.grid.ac/institutes/grid.413120.5", 
          "name": [
            "Division of Urology, Cook County Hospital, Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ray", 
        "givenName": "P", 
        "id": "sg:person.01171331567.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171331567.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Urology Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "Urology Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Major-Walker", 
        "givenName": "K", 
        "id": "sg:person.01204770464.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204770464.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Biomedical Data Sciences, GlaxoSmithKline, Research Triangle Park, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "Biomedical Data Sciences, GlaxoSmithKline, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shannon", 
        "givenName": "J", 
        "id": "sg:person.0762406761.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762406761.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Urology Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC, USA", 
          "id": "http://www.grid.ac/institutes/grid.418019.5", 
          "name": [
            "Urology Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rittmaster", 
        "givenName": "R", 
        "id": "sg:person.01013173747.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013173747.36"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2006-12-26", 
    "datePublishedReg": "2006-12-26", 
    "description": "The dual 5\u03b1-reductase inhibitor, dutasteride has been shown to suppress serum dihydrotestosterone (DHT) by >90%. In the present study, the effect of dutasteride 0.5\u2009mg/day on intraprostatic DHT levels was investigated. In this multicenter, double-blind trial, 43 men with benign prostatic hyperplasia (BPH) scheduled to undergo transurethral resection of the prostate (TURP) were randomized to receive dutasteride, 0.5\u2009mg/day or placebo for 3 months before surgery. Intraprostatic DHT, testosterone and dutasteride levels were determined at the time of TURP. Changes in serum DHT and testosterone from baseline, and both serum and intraprostatic dutasteride levels at the time of TURP were also assessed. Dutasteride reduced intraprostatic DHT by 94% relative to placebo (P<0.001); the adjusted mean intraprostatic DHT concentration was 3.23 and 0.209\u2009ng/g in the placebo and dutasteride groups, respectively. In the dutasteride group, serum DHT was reduced from baseline by 93% at month 3, a significantly greater reduction (P<0.001) than the 15% decrease observed in the placebo group. There was a reciprocal increase in intraprostatic testosterone but the level of intraprostatic testosterone in the dutasteride group tended to be lower than the intraprostatic DHT level in the placebo group (P=0.06). Significant intraprostatic DHT suppression was achieved in all subjects who received dutasteride, regardless of the level of intraprostatic dutasteride. There was a strong positive correlation between serum and intraprostatic dutasteride concentrations (R2=0.73). After 3 months of treatment, dutasteride 0.5\u2009mg/day provided near-complete suppression of both intraprostatic and serum DHT in men with BPH.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.pcan.4500931", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1119336", 
        "issn": [
          "1365-7852", 
          "1476-5608"
        ], 
        "name": "Prostate Cancer and Prostatic Diseases", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "keywords": [
      "benign prostatic hyperplasia", 
      "intraprostatic DHT levels", 
      "time of TURP", 
      "serum dihydrotestosterone", 
      "dutasteride group", 
      "dutasteride 0.5", 
      "intraprostatic dihydrotestosterone", 
      "intraprostatic testosterone", 
      "placebo group", 
      "prostatic hyperplasia", 
      "DHT levels", 
      "dual 5\u03b1-reductase inhibitor", 
      "effect of dutasteride", 
      "double-blind trial", 
      "months of treatment", 
      "DHT suppression", 
      "transurethral resection", 
      "month 3", 
      "dihydrotestosterone concentrations", 
      "DHT concentrations", 
      "dutasteride", 
      "dihydrotestosterone", 
      "placebo", 
      "reciprocal increase", 
      "testosterone", 
      "TURP", 
      "greater reduction", 
      "hyperplasia", 
      "men", 
      "baseline", 
      "months", 
      "present study", 
      "strong positive correlation", 
      "days", 
      "positive correlation", 
      "group", 
      "complete suppression", 
      "multicenter", 
      "resection", 
      "levels", 
      "surgery", 
      "suppression", 
      "prostate", 
      "trials", 
      "treatment", 
      "inhibitors", 
      "concentration", 
      "subjects", 
      "effect", 
      "decrease", 
      "study", 
      "time", 
      "increase", 
      "correlation", 
      "reduction", 
      "changes", 
      "dutasteride levels", 
      "intraprostatic dutasteride levels", 
      "intraprostatic DHT concentration", 
      "Significant intraprostatic DHT suppression", 
      "intraprostatic DHT suppression", 
      "intraprostatic dutasteride", 
      "intraprostatic dutasteride concentrations", 
      "dutasteride concentrations", 
      "intraprostatic dihydrotestosterone concentrations"
    ], 
    "name": "The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia", 
    "pagination": "149-154", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034769216"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.pcan.4500931"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17189955"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.pcan.4500931", 
      "https://app.dimensions.ai/details/publication/pub.1034769216"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_416.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.pcan.4500931"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500931'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500931'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500931'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500931'


 

This table displays all metadata directly associated to this object as RDF triples.

207 TRIPLES      21 PREDICATES      102 URIs      94 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.pcan.4500931 schema:about N0655727df57147ffa7949065dea9c24f
2 N08fb61564a354ec88f920d8190e03475
3 N1547a716dda0484397dc24cd9d437448
4 N2ca15716ca9f4607990861add80eb3b3
5 N59b227c5242b4b80b2001ca01662aaff
6 N710035948f5f461aa4cb200924b30563
7 N90416eb8e32843ac943edc7564da7d2a
8 N9b456b7716a64fb996c2ee9154c6ec9b
9 Nab449b43c7eb4b228f0ab987b1edb5d6
10 Nae5dcd049be343c19e5b5a74cbb7b9f6
11 Nec4a678501ab440ebabe0a0b8a1c0b17
12 anzsrc-for:11
13 anzsrc-for:1103
14 schema:author N5c887e8d549d4420b0886d26c78abfa6
15 schema:datePublished 2006-12-26
16 schema:datePublishedReg 2006-12-26
17 schema:description The dual 5α-reductase inhibitor, dutasteride has been shown to suppress serum dihydrotestosterone (DHT) by >90%. In the present study, the effect of dutasteride 0.5 mg/day on intraprostatic DHT levels was investigated. In this multicenter, double-blind trial, 43 men with benign prostatic hyperplasia (BPH) scheduled to undergo transurethral resection of the prostate (TURP) were randomized to receive dutasteride, 0.5 mg/day or placebo for 3 months before surgery. Intraprostatic DHT, testosterone and dutasteride levels were determined at the time of TURP. Changes in serum DHT and testosterone from baseline, and both serum and intraprostatic dutasteride levels at the time of TURP were also assessed. Dutasteride reduced intraprostatic DHT by 94% relative to placebo (P<0.001); the adjusted mean intraprostatic DHT concentration was 3.23 and 0.209 ng/g in the placebo and dutasteride groups, respectively. In the dutasteride group, serum DHT was reduced from baseline by 93% at month 3, a significantly greater reduction (P<0.001) than the 15% decrease observed in the placebo group. There was a reciprocal increase in intraprostatic testosterone but the level of intraprostatic testosterone in the dutasteride group tended to be lower than the intraprostatic DHT level in the placebo group (P=0.06). Significant intraprostatic DHT suppression was achieved in all subjects who received dutasteride, regardless of the level of intraprostatic dutasteride. There was a strong positive correlation between serum and intraprostatic dutasteride concentrations (R2=0.73). After 3 months of treatment, dutasteride 0.5 mg/day provided near-complete suppression of both intraprostatic and serum DHT in men with BPH.
18 schema:genre article
19 schema:inLanguage en
20 schema:isAccessibleForFree false
21 schema:isPartOf N00e5da19665b4632bf33f962486d01e1
22 N212156c4c3f74257ad2a16dca58bd512
23 sg:journal.1119336
24 schema:keywords DHT concentrations
25 DHT levels
26 DHT suppression
27 Significant intraprostatic DHT suppression
28 TURP
29 baseline
30 benign prostatic hyperplasia
31 changes
32 complete suppression
33 concentration
34 correlation
35 days
36 decrease
37 dihydrotestosterone
38 dihydrotestosterone concentrations
39 double-blind trial
40 dual 5α-reductase inhibitor
41 dutasteride
42 dutasteride 0.5
43 dutasteride concentrations
44 dutasteride group
45 dutasteride levels
46 effect
47 effect of dutasteride
48 greater reduction
49 group
50 hyperplasia
51 increase
52 inhibitors
53 intraprostatic DHT concentration
54 intraprostatic DHT levels
55 intraprostatic DHT suppression
56 intraprostatic dihydrotestosterone
57 intraprostatic dihydrotestosterone concentrations
58 intraprostatic dutasteride
59 intraprostatic dutasteride concentrations
60 intraprostatic dutasteride levels
61 intraprostatic testosterone
62 levels
63 men
64 month 3
65 months
66 months of treatment
67 multicenter
68 placebo
69 placebo group
70 positive correlation
71 present study
72 prostate
73 prostatic hyperplasia
74 reciprocal increase
75 reduction
76 resection
77 serum dihydrotestosterone
78 strong positive correlation
79 study
80 subjects
81 suppression
82 surgery
83 testosterone
84 time
85 time of TURP
86 transurethral resection
87 treatment
88 trials
89 schema:name The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia
90 schema:pagination 149-154
91 schema:productId N49d90727c19f4eebaf845d676b2c2bba
92 Nb296b9e5523d45bb8101f9fb84aef854
93 Ndb2e0a977bf94c4a865ade1cfe81b98d
94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034769216
95 https://doi.org/10.1038/sj.pcan.4500931
96 schema:sdDatePublished 2022-01-01T18:15
97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
98 schema:sdPublisher Nf3c51e83330b442192fef78c7c7141f6
99 schema:url https://doi.org/10.1038/sj.pcan.4500931
100 sgo:license sg:explorer/license/
101 sgo:sdDataset articles
102 rdf:type schema:ScholarlyArticle
103 N00e5da19665b4632bf33f962486d01e1 schema:volumeNumber 10
104 rdf:type schema:PublicationVolume
105 N0655727df57147ffa7949065dea9c24f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Double-Blind Method
107 rdf:type schema:DefinedTerm
108 N08fb61564a354ec88f920d8190e03475 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Prostate
110 rdf:type schema:DefinedTerm
111 N1547a716dda0484397dc24cd9d437448 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Aged
113 rdf:type schema:DefinedTerm
114 N212156c4c3f74257ad2a16dca58bd512 schema:issueNumber 2
115 rdf:type schema:PublicationIssue
116 N2ca15716ca9f4607990861add80eb3b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Humans
118 rdf:type schema:DefinedTerm
119 N481345c8689e47979a4448ed61d3e5bd rdf:first sg:person.0762406761.71
120 rdf:rest Nd0833822d535479db0b4134f0fda8e4b
121 N49d90727c19f4eebaf845d676b2c2bba schema:name pubmed_id
122 schema:value 17189955
123 rdf:type schema:PropertyValue
124 N59b227c5242b4b80b2001ca01662aaff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Azasteroids
126 rdf:type schema:DefinedTerm
127 N5c887e8d549d4420b0886d26c78abfa6 rdf:first sg:person.01035712243.26
128 rdf:rest Nf447faacece24de1a0c2320a5972c630
129 N710035948f5f461aa4cb200924b30563 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Dihydrotestosterone
131 rdf:type schema:DefinedTerm
132 N90416eb8e32843ac943edc7564da7d2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Male
134 rdf:type schema:DefinedTerm
135 N9b456b7716a64fb996c2ee9154c6ec9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Prostatic Hyperplasia
137 rdf:type schema:DefinedTerm
138 Nab449b43c7eb4b228f0ab987b1edb5d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Dutasteride
140 rdf:type schema:DefinedTerm
141 Nae5dcd049be343c19e5b5a74cbb7b9f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Testosterone
143 rdf:type schema:DefinedTerm
144 Nb296b9e5523d45bb8101f9fb84aef854 schema:name dimensions_id
145 schema:value pub.1034769216
146 rdf:type schema:PropertyValue
147 Nd0833822d535479db0b4134f0fda8e4b rdf:first sg:person.01013173747.36
148 rdf:rest rdf:nil
149 Ndb2e0a977bf94c4a865ade1cfe81b98d schema:name doi
150 schema:value 10.1038/sj.pcan.4500931
151 rdf:type schema:PropertyValue
152 Nec4a678501ab440ebabe0a0b8a1c0b17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Middle Aged
154 rdf:type schema:DefinedTerm
155 Nef54f10e779a434caf37afb572e4e727 rdf:first sg:person.01204770464.24
156 rdf:rest N481345c8689e47979a4448ed61d3e5bd
157 Nf3c51e83330b442192fef78c7c7141f6 schema:name Springer Nature - SN SciGraph project
158 rdf:type schema:Organization
159 Nf447faacece24de1a0c2320a5972c630 rdf:first sg:person.01171331567.29
160 rdf:rest Nef54f10e779a434caf37afb572e4e727
161 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
162 schema:name Medical and Health Sciences
163 rdf:type schema:DefinedTerm
164 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
165 schema:name Clinical Sciences
166 rdf:type schema:DefinedTerm
167 sg:journal.1119336 schema:issn 1365-7852
168 1476-5608
169 schema:name Prostate Cancer and Prostatic Diseases
170 schema:publisher Springer Nature
171 rdf:type schema:Periodical
172 sg:person.01013173747.36 schema:affiliation grid-institutes:grid.418019.5
173 schema:familyName Rittmaster
174 schema:givenName R
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013173747.36
176 rdf:type schema:Person
177 sg:person.01035712243.26 schema:affiliation grid-institutes:None
178 schema:familyName Wurzel
179 schema:givenName R
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035712243.26
181 rdf:type schema:Person
182 sg:person.01171331567.29 schema:affiliation grid-institutes:grid.413120.5
183 schema:familyName Ray
184 schema:givenName P
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171331567.29
186 rdf:type schema:Person
187 sg:person.01204770464.24 schema:affiliation grid-institutes:grid.418019.5
188 schema:familyName Major-Walker
189 schema:givenName K
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204770464.24
191 rdf:type schema:Person
192 sg:person.0762406761.71 schema:affiliation grid-institutes:grid.418019.5
193 schema:familyName Shannon
194 schema:givenName J
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762406761.71
196 rdf:type schema:Person
197 grid-institutes:None schema:alternateName Department of Urology, Grove Hill Medical Center, New Britain, CT, USA
198 schema:name Department of Urology, Grove Hill Medical Center, New Britain, CT, USA
199 rdf:type schema:Organization
200 grid-institutes:grid.413120.5 schema:alternateName Division of Urology, Cook County Hospital, Chicago, IL, USA
201 schema:name Division of Urology, Cook County Hospital, Chicago, IL, USA
202 rdf:type schema:Organization
203 grid-institutes:grid.418019.5 schema:alternateName Biomedical Data Sciences, GlaxoSmithKline, Research Triangle Park, NC, USA
204 Urology Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC, USA
205 schema:name Biomedical Data Sciences, GlaxoSmithKline, Research Triangle Park, NC, USA
206 Urology Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC, USA
207 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...